Literature DB >> 11317251

Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999.

H Valdez1, T K Chowdhry, R Asaad, I J Woolley, T Davis, R Davidson, N Beinker, B M Gripshover, R A Salata, G McComsey, S B Weissman, M M Lederman.   

Abstract

We analyzed the deaths in an outpatient human immunodeficiency virus (HIV) care clinic at University Hospitals in Cleveland from January 1995 through December 1999. The number of annual deaths decreased progressively, from 112 in 1995 to 32 in 1999. The median final CD4(+) cell count before death increased progressively from 10 cells/microL in 1995 to 90 cells/microL in 1999 (P<.01); 20%--25% of patients who died from 1997 through 1999 had plasma HIV RNA levels below detection limits. From 1995 through 1998, deaths due to infection, to end-stage acquired immune deficiency syndrome, and to malignancies decreased, whereas the proportion of deaths due to end-organ failures and of uncertain relationship to HIV infection increased. The spectrum of mortality in HIV disease has changed recently; although opportunistic infections cause death less frequently, deaths are occurring in people who have control of HIV replication and with some preservation of immune function. These observations underscore the need to monitor the etiologies of HIV-associated mortality and to better our understanding of the relationships among immune defenses, treatment-related toxicities, and end-organ failure in patients with HIV disease.

Entities:  

Mesh:

Year:  2000        PMID: 11317251     DOI: 10.1086/320164

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy.

Authors:  D Chadwick; J Pido-Lopez; A Pires; N Imami; F Gotch; J S Villacian; S Ravindran; N I Paton
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 2.  Reporting of deaths during pre-approval clinical trials for advanced HIV-infected populations.

Authors:  Rosemary Johann-Liang; Andrea N James; Virginia L Behr; Kimberly Struble; Debra B Birnkrant
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults.

Authors:  P Freitas; D Carvalho; A C Santos; J Mesquita; F Correia; S Xerinda; R Marques; E Martinez; A Sarmento; J L Medina
Journal:  J Endocrinol Invest       Date:  2011-07-05       Impact factor: 4.256

4.  Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.

Authors:  Claire Pressiat; Veronique Mea-Assande; Caroline Yonaba; Jean-Marc Treluyer; Désiré-Lucien Dahourou; Madeleine Amorissani-Folquet; Stéphane Blanche; François Eboua; Diarra Ye; Gabrielle Lui; Karen Malateste; Yi Zheng; Valeriane Leroy; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

5.  Comparing outcomes of HIV versus non-HIV patients requiring mechanical ventilation.

Authors:  Vikas Pathak; Iliana Samara Hurtado Rendon; Shebli Atrash; Vinay Prasad Rao Gagadam; Kaushik Bhunia; Syam Prasad Mallampalli; Vijay Vegesna; Mahesh Mani Dangal; Ronald L Ciubotaru
Journal:  Clin Med Res       Date:  2011-10-26

6.  Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy.

Authors:  P Freitas; D Carvalho; A C Santos; M J Matos; A J Madureira; R Marques; E Martinez; A Sarmento; J L Medina
Journal:  J Endocrinol Invest       Date:  2011-12-16       Impact factor: 4.256

7.  Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996.

Authors:  Robert S Levine; Nathaniel C Briggs; Barbara S Kilbourne; William D King; Yvonne Fry-Johnson; Peter T Baltrus; Baqar A Husaini; George S Rust
Journal:  Am J Public Health       Date:  2007-08-29       Impact factor: 9.308

8.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

9.  Renal transplantation in a HIV positive patient.

Authors:  A Mann; P Soundararajan; S Shroff
Journal:  Indian J Nephrol       Date:  2009-07

10.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Authors:  Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.